Payment overview · 2025
General Payments
$215.46
10 reported records · 6 companies
Healthcare provider profile · identity verified
John F Mcleod, MD
Allopathic & Osteopathic Physicians|Family Medicine · CHERAW, SC · NPI 1154480028
Verified facts
What the public records show
CMS Open Payments records show John F Mcleod, MD received $215.46 in general payments during 2025 across 10 reported records.
Dexcom, Inc. accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $46.66 | 21.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.88 | 21.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.29 | 17.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.02 | 16.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.50 | 14.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.11 | 8.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $183.19 | 9 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $46.66 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.88 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.29 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.02 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.50 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 144 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 149 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
83 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
144 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
149 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 1187 | 192 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1081 | 248 |
| Levothyroxine Sodium | Levothyroxine Sodium | 758 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 746 | 168 |
| Omeprazole | Omeprazole | 643 | 128 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 557 | 95 |
| Potassium Chloride | Potassium Chloride | 501 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 470 | 112 |
| Metformin Hcl | Metformin Hcl | 438 | 94 |
| Lisinopril | Lisinopril | 420 | 94 |
| Tramadol Hcl | Tramadol Hcl | 385 | 78 |
| Glipizide | Glipizide | 376 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 344 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 314 | 81 |
| Meloxicam | Meloxicam | 313 | 76 |
| Gabapentin | Gabapentin | 305 | 81 |
| Losartan Potassium | Losartan Potassium | 293 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 293 | 73 |
| Furosemide | Furosemide | 291 | 75 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 287 | 79 |
| Valsartan | Valsartan | 278 | 54 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 269 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 247 | 55 |
| Allopurinol | Allopurinol | 230 | 54 |
| Eliquis | Apixaban | 213 | 39 |
| Montelukast Sodium | Montelukast Sodium | 212 | 40 |
| Doxazosin Mesylate | Doxazosin Mesylate | 209 | 46 |
| Simvastatin | Simvastatin | 206 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 192 | 41 |
| Metformin Hcl Er | Metformin Hcl | 191 | 52 |
| Doxycycline Hyclate | Doxycycline Hyclate | 188 | 136 |
| Famotidine | Famotidine | 181 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 177 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 175 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 166 | 63 |
| Clonazepam | Clonazepam | 165 | 25 |
| Januvia | Sitagliptin Phosphate | 157 | 23 |
| Trazodone Hcl | Trazodone Hcl | 152 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 151 | 35 |
| Prednisone | Prednisone | 150 | 82 |
| Ozempic | Semaglutide | 149 | 26 |
| Jardiance | Empagliflozin | 144 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 141 | 60 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 132 | 30 |
| Benazepril Hcl | Benazepril Hcl | 130 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 124 | 20 |
| Nifedipine Er | Nifedipine | 116 | 22 |
| Atenolol | Atenolol | 107 | 19 |
| Temazepam | Temazepam | 105 | 20 |
| Carvedilol | Carvedilol | 103 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 24 |
| Bupropion Xl | Bupropion Hcl | 101 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 101 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 96 | 17 |
| Telmisartan | Telmisartan | 95 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 30 |
| Ezetimibe | Ezetimibe | 94 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 94 | 24 |
| Ibuprofen | Ibuprofen | 85 | 24 |
| Farxiga | Dapagliflozin Propanediol | 83 | 20 |
| Methocarbamol | Methocarbamol | 83 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 14 |
| Cefdinir | Cefdinir | 77 | 41 |
| Labetalol Hcl | Labetalol Hcl | 77 | 13 |
| Lorazepam | Lorazepam | 76 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 75 | 18 |
| Finasteride | Finasteride | 72 | 12 |
| Glipizide Er | Glipizide | 68 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 63 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 53 |
| Trulicity | Dulaglutide | 62 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 60 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 59 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 58 | suppressed |
| Xarelto | Rivaroxaban | 58 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 14 |
| Pregabalin | Pregabalin | 56 | 11 |
| Sertraline Hcl | Sertraline Hcl | 56 | 13 |
| Spironolactone | Spironolactone | 54 | 11 |
| Alendronate Sodium | Alendronate Sodium | 52 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 52 | suppressed |
| Diazepam | Diazepam | 51 | suppressed |
| Mirtazapine | Mirtazapine | 51 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 51 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 12 |
| Synthroid | Levothyroxine Sodium | 49 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 11 |
| Chlorthalidone | Chlorthalidone | 47 | 12 |
| Fenofibrate | Fenofibrate,micronized | 45 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 45 | 16 |
| Ketoconazole | Ketoconazole | 44 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | 12 |
| Hydrocortisone | Hydrocortisone | 41 | 25 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 41 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 39 | suppressed |
| Nitroglycerin | Nitroglycerin | 38 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | suppressed |
| Estradiol | Estradiol | 33 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 17 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Nabumetone | Nabumetone | 28 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 28 | suppressed |
| Roflumilast | Roflumilast | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 12 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Felodipine Er | Felodipine | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 12 |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Triazolam | Triazolam | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Klor-Con M10 | Potassium Chloride | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Fycompa | Perampanel | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Vimpat | Lacosamide | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $215.46 · 10 records | Dexcom, Inc. | BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, Fluad, Flucelvax, JARDIANCE, Ozempic, Rybelsus | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error